{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metabolic+Disease&page=18",
    "query": {
      "condition": "Metabolic Disease",
      "page": 18
    },
    "page_size": 10
  },
  "pagination": {
    "page": 18,
    "page_size": 10,
    "total_count": 18719,
    "total_pages": 1872,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metabolic+Disease&page=19&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metabolic+Disease&page=17&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T17:50:31.555Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05145816",
      "title": "Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "AL Amyloidosis",
        "Amyloidosis"
      ],
      "interventions": [
        {
          "name": "Belantamab mafodotin 2.5 mg/kg (8 weeks)",
          "type": "DRUG"
        },
        {
          "name": "Belantamab mafodotin 1.9 mg/kg (8 weeks)",
          "type": "DRUG"
        },
        {
          "name": "Belantamab mafodotin 1.4 mg/kg (12 weeks)",
          "type": "DRUG"
        },
        {
          "name": "Belantamab mafodotin 1.9 mg/kg (12 weeks)",
          "type": "DRUG"
        },
        {
          "name": "Belantamab mafodotin every 8 weeks or 12 weeks as determined by Part 1 recommended dosages",
          "type": "DRUG"
        },
        {
          "name": "Belantamab mafodotin 1.0 mg/kg (12 weeks)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2024-02-15",
      "completion_date": "2027-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-10-15T17:50:31.555Z",
      "location_count": 3,
      "location_summary": "Nashville, Tennessee • Dallas, Texas • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05145816"
    },
    {
      "nct_id": "NCT00775684",
      "title": "Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pre-diabetes",
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Exenatide",
          "type": "DRUG"
        },
        {
          "name": "Sitagliptin",
          "type": "DRUG"
        },
        {
          "name": "Glimepiride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 47,
      "start_date": "2008-10",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2022-06-07",
      "last_synced_at": "2026-10-15T17:50:31.555Z",
      "location_count": 3,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00775684"
    },
    {
      "nct_id": "NCT00151749",
      "title": "WelChol® and Insulin in Treating Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Colesevelam hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 260,
      "start_date": "2004-06",
      "completion_date": "2005-12",
      "has_results": false,
      "last_update_posted_date": "2012-01-18",
      "last_synced_at": "2026-10-15T17:50:31.555Z",
      "location_count": 45,
      "location_summary": "Tuscumbia, Alabama • Sierra Vista, Arizona • Jonesboro, Arkansas + 42 more",
      "locations": [
        {
          "city": "Tuscumbia",
          "state": "Alabama"
        },
        {
          "city": "Sierra Vista",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Searcy",
          "state": "Arkansas"
        },
        {
          "city": "Carmichael",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00151749"
    },
    {
      "nct_id": "NCT01151592",
      "title": "Safety Assessment of Iron Sucrose (Venofer) in Patients With Chronic Kidney Disease Who Cannot Tolerate Ferumoxytol (Feraheme) or Iron Dextran (INFed or Dexferrum)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Iron Deficiency Anemia"
      ],
      "interventions": [
        {
          "name": "Iron Sucrose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "American Regent, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2018-01-24",
      "last_synced_at": "2026-10-15T17:50:31.555Z",
      "location_count": 1,
      "location_summary": "Norristown, Pennsylvania",
      "locations": [
        {
          "city": "Norristown",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01151592"
    },
    {
      "nct_id": "NCT02520336",
      "title": "Postpartum Diabetes Screening in Women With Gestational Diabetes",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes, Gestational"
      ],
      "interventions": [
        {
          "name": "Reminder",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 78,
      "start_date": "2015-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-08-11",
      "last_synced_at": "2026-10-15T17:50:31.555Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02520336"
    },
    {
      "nct_id": "NCT07199244",
      "title": "The Immediate and Long-term Effects of a Novel Marine-based Iron Supplement in Adult Females",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Anemia",
        "Iron Deficiency (Without Anemia)",
        "Iron Absorption"
      ],
      "interventions": [
        {
          "name": "marine-based heme iron",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Nutraceuticals Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "42 Years",
        "sex": "FEMALE",
        "summary": "21 Years to 42 Years · Female only"
      },
      "enrollment_count": 61,
      "start_date": "2024-08-01",
      "completion_date": "2025-10",
      "has_results": false,
      "last_update_posted_date": "2025-09-30",
      "last_synced_at": "2026-10-15T17:50:31.555Z",
      "location_count": 1,
      "location_summary": "Huntsville, Alabama",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07199244"
    },
    {
      "nct_id": "NCT00501709",
      "title": "Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Belatacept and Raptiva",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 10,
      "start_date": "2007-02",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2020-05-06",
      "last_synced_at": "2026-10-15T17:50:31.555Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00501709"
    },
    {
      "nct_id": "NCT00694109",
      "title": "An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lipid Metabolism, Inborn Errors",
        "Hypercholesterolemia, Autosomal Dominant",
        "Hyperlipidemias",
        "Metabolic Diseases",
        "Hyperlipoproteinemia Type II",
        "Metabolism, Inborn Errors",
        "Genetic Diseases, Inborn",
        "Infant, Newborn, Diseases",
        "Metabolic Disorder",
        "Congenital Abnormalities",
        "Hypercholesterolemia",
        "Hyperlipoproteinemias",
        "Dyslipidemias",
        "Lipid Metabolism Disorders"
      ],
      "interventions": [
        {
          "name": "Mipomersen Sodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kastle Therapeutics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 144,
      "start_date": "2008-04",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2016-09-09",
      "last_synced_at": "2026-10-15T17:50:31.555Z",
      "location_count": 20,
      "location_summary": "Mission Viejo, California • Newport Beach, California • Bridgeport, Connecticut + 17 more",
      "locations": [
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Bridgeport",
          "state": "Connecticut"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00694109"
    },
    {
      "nct_id": "NCT00859898",
      "title": "Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Metformin XR",
          "type": "DRUG"
        },
        {
          "name": "dapagliflozin matching Placebo",
          "type": "DRUG"
        },
        {
          "name": "metformin HCl Modified Release matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "77 Years",
        "sex": "ALL",
        "summary": "18 Years to 77 Years"
      },
      "enrollment_count": 1093,
      "start_date": "2009-04",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2016-07-07",
      "last_synced_at": "2026-10-15T17:50:31.555Z",
      "location_count": 64,
      "location_summary": "Ozark, Alabama • Tempe, Arizona • Concord, California + 53 more",
      "locations": [
        {
          "city": "Ozark",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Encinitas",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00859898"
    },
    {
      "nct_id": "NCT02178787",
      "title": "UTLight-transcranial Doppler Assessment of Regional Cerebral Autoregulation",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 60,
      "start_date": "2014-04",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2017-06-16",
      "last_synced_at": "2026-10-15T17:50:31.555Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02178787"
    }
  ]
}